Fostering Multidisciplinary Care May Reduce Oncologist Workplace Burnout
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Related Articles
Breastfeeding Support May Reduce TNBC Incidence, Mitigate Disparities
Policy changes supporting breastfeeding may address structural barriers and lower overall incidence and racial disparities surrounding TNBC in the US.
ProstACT GLOBAL Results May Support “Open” Decisions in Metastatic CRPC
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Communication Between Leadership and Clinicians Improves Cancer Care
Leaders of a new cancer center, which is part of JFK University Medical Center, discuss how they can support frontline clinicians.
Chemoradiation Shows Responses Across Dose Levels in Anal Cancer
Phase 2 data indicate that reduced-dose chemoradiotherapy may be tolerable among patients with early-stage anal cancer.
Durvalumab Combo Demonstrates DFS Improvement in High-Risk NMIBC
Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.
Frontline Efti Combo Yields Meaningful Survival in PD-L1–Low HNSCC
Survival data with eftilagimod alfa plus pembrolizumab compare favorably with historical results seen with standard-of-care therapies in this population.
Highlighting “Trickle Down” Progress in Developing Rare Lymphoma Treatment
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
Lurbinectedin/Pembrolizumab Shows Significant Activity in Relapsed SCLC
Findings from the phase 1/2 LUPER trial support further assessment of lurbinectedin plus pembrolizumab in relapsed small cell lung cancer.
ADCs in HER2+ Gastric Cancer
Experts discuss the factors supporting the choice of trastuzumab deruxtecan following disease progression and its mechanism of action in addressing resistance to prior HER2-targeted therapy…
Melphalan/Hepatic Delivery System Demonstrates Benefit in Uveal Melanoma
No treatment-related deaths were observed among patients with metastatic uveal melanoma treated with melphalan and a hepatic delivery system.
